MS-MLPA Protocol Two-Tube TMSP-V001
MS-MLPA Protocol Two-Tube TMSP-V001
MLPA
The SALSA PCR buffer required for the two-tube protocol is no longer included in an MLPA reagent
kit. It can be ordered on special request free of charge.
The enzyme dilution buffer is no longer needed.
The polymerase mix for PCR reaction should be added at room temperature! Never use a hot start.
NEW DOCUMENT. Fully reviewed MS-MLPA General Protocol completely adapted for use with the two-tube
method.
www.mlpa.com
page 1 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
MLPA
Table of Contents
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
When hybridising to an unmethylated DNA target, the methylation-specific probe will be ligated and simultaneously
digested by HhaI (Error! Reference source not found.; 3B bottom). A digested MS-MLPA probe will not generate a
peak signal because it cannot be amplified. In contrast, when the target sequence of the MS-MLPA probe is
methylated, the methyl group will prevent HhaI-digestion (Error! Reference source not found.; 3B top). An
undigested, ligated probe can be amplified during PCR, resulting in a normal peak signal.
MLPA is a relative technique: only relative differences can be detected by comparing the MLPA peak patterns of DNA
samples. Inclusion of reference samples in the same run is therefore essential. (See 7 DATA ANALYSIS.) Comparing
the electrophoresis patterns of the undigested MS-MLPA reactions allows for the detection of copy number changes
(Figure 2, top). Comparing the peak patterns of digested reactions may reveal unusual methylation of DNA target
sequences (Figure 2; bottom).
www.mlpa.com
page 2 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
REFERENCE SAMPLE
Undigested reaction
MLPA
TUMOUR SAMPLE
Undigested reaction
Digested reaction
Digested reaction
Figure 2 Top: The tumour sample displays the same peak pattern as the normal reference sample, indicating there are no copy
number aberrations. Bottom: The digested reaction of the reference sample only shows peaks from probes lacking the HhaI
restriction site. For this application (ME001 probemix), all probe targets containing a HhaI-site are normally unmethylated and are
therefore digested. In contrast, in the digested tumour sample, extra peaks can be seen. Targets that are normally unmethylated
and therefore digested are methylated in this tumour sample.
Figure 3 Copy number changes as displayed by Coffalyser.Net software. Left: three probes in the test sample (bottom) are
found to have a reduced peak signal as compared to the reference sample (top). Right: Results after analysis by Coffalyser.Net:
arranging probes by chromosomal location shows a reduced copy number for the three adjacent probes.
Results of MS-MLPA tests depend on several factors, including sample purity, experimental setup (selection of test
and reference samples), instrument settings, data normalisation method, quality of the HhaI enzyme. For reliable MSMLPA results, the standard deviation for each MS-MLPA probe should be below 10% when testing normal DNA
samples. It is essential to follow the procedures described in this protocol accurately. Separate protocols exist for
standard MLPA (detection of copy number changes only) and RNA quantification (RT-MLPA).
Item no.
Description
EK1-FAM
EK1-Cy5
EK5-FAM
EK5-Cy5
PCR001-FAM
PCR001-Cy5
PCR003-FAM
SALSA MLPA EK1 reagent kit 100 rxn SALSA MLPA EK1 reagent kit 100 rxn SALSA MLPA EK5 reagent kit 500 rxn SALSA MLPA EK5 reagent kit 500 rxn SALSA MLPA PCR kit 100 rxn - FAM
SALSA MLPA PCR kit 100 rxn - Cy5
SALSA MLPA PCR kit 300 rxn - FAM
www.mlpa.com
FAM
Cy5
FAM
Cy5
page 3 of 17
MRC-Holland
2.2.
COMPONENTS PROVIDED PER SALSA MLPA REAGENT KIT1 (100 OR 500 REACTIONS)
Reagent kit
component
SALSA MLPA Buffer
(yellow cap) 2
SALSA Ligase-65
(green cap)
Ligase Buffer A
(transparent cap) 3
Ligase Buffer B
(white cap)
SALSA PCR Primer
Mix (brown cap)
SALSA Polymerase
(orange cap)
1
2
3
4
5
6
2.3.
Volumes
EK1
Ingredients
EK5
115 l 5115 l
240 l 5240 l
65 l
565 l
Additional Component
Volume
4
2.4.
Product Description
2
3
Available Volumes
Ingredients
40 l (25R), 80 l (50R),
160 l (100R)
N/A
480 l
Ingredients
Application-specific
MLPA probemix
2.5.
MLPA
Volumes
PCR001
PCR003
240 l
3x 240 l
65 l
3x 65 l
N/A
N/A
Ingredients
Synthetic oligonucleotides with fluorescent dye (FAM, Cy5, IRD800, ROX or
unlabeled), dNTPs, Tris-HCl, KCl, EDTA, BRIJ. pH 8
Glycerol, non-ionic detergents, EDTA, DTT (0.1 %), KCl, Tris-HCl, Polymerase
enzyme (bacterial origin). pH 7.5
N/A
None of the ingredients are hazardous in the amount present in an MS-MLPA kit as defined in the Hazard
Communication Standard (HCS). None of the ingredients are of human or animal origin or are derived from
pathogenic bacteria. None of the preparations provided in this kit contain dangerous substances as defined in
European Directive 67/548/EC and its amendments at concentrations requiring distribution of Material Safety Data
Sheets as specified in European Directives 1999/45/EC and 2001/58/EC. Material Safety Data Sheets are not required
for these products.
2.6.
All components of the SALSA MS-MLPA kit must be stored directly upon arrival between -25C and -15C, shielded
from light and in the original packaging. When stored under the recommended conditions, a shelf life of at least 1
year is guaranteed, also after opening. See the labels on each vial for the exact expiry date.
1
2
3
4
For reverse transcriptase MLPA, separate reagent kits are available, see the General RT-MLPA protocol (EK1-RT, EK5-RT).
The improved MLPA buffer, introduced in January 2013, can be recognised by its yellow label.
The coenzyme NAD in ligase buffer A is sensitive to repeated freeze/thawing; it may deteriorate after more than 20 freeze/thaw cycles.
SALSA PCR buffer is required for this two-tube protocol and can be ordered free of charge on request.
www.mlpa.com
page 4 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
www.mlpa.com
MLPA
page 5 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
2.7.
2.8.
MLPA
SAMPLE TREATMENT
1. Use a total quantity of 50-250 ng (optimum: 50-100 ng) of human DNA in a 5 l 5 volume for each MLPA
reaction6. If necessary, DNA samples can be concentrated by ethanol precipitation. (Glycogen (Roche
901393) can be used as carrier.) 7
2. Dissolve and dilute sample DNA in TE (10 mM Tris-HCl pH 8.2 + 0.1 mM EDTA). DNA preparation should
have pH: 8.0-8.5 to prevent depurination during initial heat treatment at 98o C. If unknown whether
sufficient TE is present in the sample, add Tris-HCl: 4l sample DNA + 1l 50mM Tris-HCl pH 8.5
3. Extraction methods should not leave a high concentration of contaminants such as salt. Do not use Qiagen
EZ1, M6, M48 and M96 systems, unless an alternative protocol is used.
4. We have tested and can recommend the following extraction methods:
Qiagen Autopure LS (automated) and QIAamp DNA mini/midi/maxi kit (manual)
Promega DNA extraction Wizard (manual)
Salting out (manual)
5. MLPA is more sensitive to contaminants than simple monoplex PCR assays. Contaminants include
(guanidinium) salts, phenol, ethanol, heparin, EDTA, Fe. To minimise the effect of contaminants, ensure
extraction methods, tissues types, concentrations and treatment are as similar as possible.
6. EDTA concentration of the samples should not be higher than 1.5 mM. Sample DNA should not be
concentrated by evaporation or SpeedVac as this leads to a very high EDTA concentration.
7. In case of doubts about DNA quality: a) use only 20-50 ng of sample DNA; b) clean contaminated samples
by ethanol precipitation or silica based clean-up kits.
8. Do not use heparinised blood for DNA extraction. Traces of heparin are very difficult to remove from DNA
preparations and can distort the MS-MLPA PCR reaction.
9. An RNAse treatment is essential when investigating genes that are highly expressed in the sample tissue
studied. E.g. HBA, HBB genes in blood-derived samples; (mitochondrial) ribosomal RNA genes (all tissues).
Never use more than 5 l sample DNA per reaction. Using more than 5 l DNA reduces the probe and salt concentration. This reduces the
hybridisation speed and the stability of the binding of MLPA probes to the sample DNA.
6
Optical density (260 nm) measurements often overestimate the DNA concentration e.g. due to contamination with RNA. Whether the DNA
quantity was sufficient can be estimated on the basis of the Q-fragments, as is explained in 6.3.
7
DNA from whole genome amplification is not recommended for MLPA because of the possible amplification bias among the target sequences.
www.mlpa.com
page 6 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
3.2.
MLPA
www.mlpa.com
page 7 of 17
MRC-Holland
4.2.
MLPA
5 minutes
pause
2) Hybridisation
3.
4.
5.
1 minute
pause
pause
reaction
95C
60C
20C
11.
12.
4.3.
35 cycles:
72C
15C
95C
60C
72C
30 seconds
30 seconds
60 seconds
20 minutes
pause
4.4.
4.5.
www.mlpa.com
page 8 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
4.6.
MLPA
Note: as compared to the PCR reaction in standard MLPA protocol, the PCR protocol for MS-MLPA described here
makes use of half volumes. Some users prefer doing the PCR using double these volumes. The optional SALSA PCR
reagents (PCR-001) can be ordered for this purpose.
1. Label 0.2 ml tubes, strips or plates of PCR reaction.
2. Prepare a PCR buffer mix containing for each reaction: 4 l SALSA PCR buffer + 26 l dH2O. Mix briefly by
vortexing.
3. Add 30 l of the PCR buffer mix to each new tube.
4. At room temperature, transfer 10 l of each ligation product to its corresponding PCR tube.
5. Vortex SALSA PCR primer mix. Warm polymerase for 10 sec in your hand to reduce viscosity.
6. Prepare polymerase master mix by adding, for each reaction: 3.75 l dH2O + 1 l SALSA PCR primer mix
(brown cap) + 0.25 l SALSA Polymerase (orange cap). Mix well by pipetting up and down; do not vortex.
Store on ice until use.
7. At room temperature8, add 5 l polymerase mix to each tube. Mix by pipetting gently up and down.
Continue thermocycler program; 35 cycles of 30 seconds 95C; 30 seconds 60C; 60 seconds 72C. End
with 20 min incubation at 72C; pause at 15C.
8. After PCR reaction, do not open tubes in the room with the thermocycler. To avoid contamination, use
different micropipettes for performing MLPA reactions and handling MLPA PCR products.
9. PCR product can be stored at 4C for 1 week. For longer periods, store between -25C /-15C. As
fluorescent dyes are light-sensitive, store PCR products in dark box or wrapped in aluminium foil.
5.2.
8
With the introduction of the new PCR primers (recognisable by the label with MRC-Holland logo) in June 2011, the temperature at which the PCR
should be prepared has been changed to Room Temperature (~20C).
www.mlpa.com
page 9 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
5.3.
MLPA
ELECTROPHORESIS SPECIFICATIONS
Instrument
MLPA
Primer
Dye
Capillaries
Injection mixture
Initial Settings
Beckman
CEQ-2000
CEQ-8000
CEQ-8800
Cy5
33 cm
FAM
36, 50 cm
ABI-Prism 310
FAM
ABI-3500:
50 cm!
47 cm
DATA VISUALIZATION
1. Visualizing your raw data (.fsa, .scf, .cqf, .esd files prior to size-calling):
a. Beckman: Coffalyser.Net or Beckman GenomeLab software.
b. ABI: Coffalyser.Net, GeneMapper, GeneMarker, Peak Scanner or Foundation Data Collection Software on
CE instrument.
2. Size-calling your data:
a. Beckman: use Coffalyser.Net or CEQ / GeXP GenomeLab software to size-call and visualise data.
b. ABI: use Coffalyser.Net, GeneMapper, GeneMarker or Peak Scanner or to size-call and then visualise
data.
6.2.
Briefly heating the injection mixture before capillary electrophoresis is essential. If this is omitted, some sequences with a high Guanine and
Cytosine content may remain double-stranded, thereby altering their mobility.
10
Rare cases are known in which this Y-specific sequence is absent in males, as well as females who carry this Y-sequence on an X-chromosome.
www.mlpa.com
page 10 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
MLPA
Q-FRAGMENTS
The 4 Quantity Fragments (Q-fragments, at 64-82 nt) measure whether sufficient DNA was added and whether
ligation was successful. The Q-fragments do not need to hybridise to the DNA or be ligated to be amplified during
PCR. The more sample DNA is added, the lower they get; see Figure .
ALL FOUR Q-FRAGMENTS HIGH: INSUFFICIENT SAMPLE DNA PRESENT OR LIGATION REACTION
FAILED!
Figure 4 Effect of DNA quantity on Q-fragments. The more sample DNA is used, the lower the Q-fragments. Shown are
MLPA results with A. 5 ng DNA, B. 10 ng, C. 50 ng.
D-FRAGMENTS
The 2 DNA Denaturation Fragments (D-fragments, at 88, 96 nt) detect a sequence in a strong CpG island. CpG islands
have a high CG content and are difficult to denature. They are low in case of denaturation problems.
When using ABI POP7, a non-specific fragment of ~87 nt is usually present and may coincide with the 88 nt Dfragment. Please note that only the appearance of all three peaks at 88, 92 and 96 nt indicates DNA contamination of
the RNA sample.
Figure 5 Effect of poor denaturation on D-fragments. D-fragments are low when sample DNA denaturation is incomplete
(here induced by adding salt). MLPA results on DNA sample containing in A. TE; B. TE + 40 mM NaCl; C. TE + 100 mM NaCl. As
MS-MLPA probes more frequently target CG-rich sequences, denaturation problems may be more prevalent in MS-MLPA.
6.3.
NO DNA REACTION
In a typical No DNA control, only the four Q-fragments are visible. However, MLPA PCR reactions are more prone to
non-specific peaks in the No DNA than a normal PCR reaction. In some probe sets, a few peaks may be visible. These
non-specific peaks should not influence MLPA results: when sufficient sample DNA is used, they are outcompeted by
the MLPA probes. Notify MRC-Holland in case a non-specific peak in the No DNA reactions is reproducibly higher than
the Q-fragments.
6.4.
EVAPORATION PROBLEMS
Evaporation occurs during (A) pipetting the ligation reaction at 54C or (B) overnight hybridization. In case you
suspect evaporation problems (see flowchart), the following may help. (A): Reduce handling time by using multichannel pipettes. (B): Test evaporation by incubating 8 l H2O overnight at 60oC; >5 l H2O should remain. To
reduce evaporation: 1. ensure heated lid works well; 2. increase/decrease pressure of lid on tubes; 3. try different
tubes (ABgene AB-0773, AB-0451); 4. use mineral oil (Vapor-lock, Qiagen): add small drop of oil to DNA sample, just
enough to cover it. There is no need to remove oil. After adding MLPA buffer-probemix mixture and polymerase mix:
centrifuge very briefly. After addition of ligase mix: gently pipet up and down.
www.mlpa.com
page 11 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
6.5.
MLPA
www.mlpa.com
page 12 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
MLPA
7. DATA ANALYSIS
Only data that has passed quality evaluation can be used for data analysis. We recommend Coffalyser.Net for MSMLPA data analysis as it has been designed by MRC-Holland as the optimal data analysis program, with a thorough
analysis algorithm and built-in quality checks. The method below describes the very basic principles of MLPA data
normalisation. For certain applications, a more thorough analysis may be required, see the probemix-specific product
description). The analysis of MS-MLPA probemixes consists of two parts:
7.1 PART 1: DETERMINING COPY NUMBERS: determine copy numbers by comparing undigested samples.
This is identical to standard MLPA and involves two steps. Note that the method described here makes use
of a normalisation constant, which offers a more thorough analysis.
7.2 PART 2: DETERMINING METHYLATION PROFILE: determine methylation patterns by comparing each
undigested sample to its digested counterpart. The second part is unique for MS-MLPA probemixes and
serves to quantify the percentage of methylation within a given sample.
7.1.
The absolute fluorescence detected by the CE instrument depends on many factors and needs to be normalised to
obtain useful MS-MLPA results. Part 1, MLPA copy number analysis, involves two normalisation steps: one within the
sample (intrasample normalisation) and one between samples (intersample normalisation).
1. Intrasample normalisation: within each (digested and undigested) sample, compare the probe peaks
detecting the target genes TO reference probe peaks. (Reference probes detect sequences that are
expected to have a normal copy number in all samples; they do not contain a site for the HhaI enzyme).
This should be done by dividing the signal of each probe by the signal of every reference probe in that
sample, thus creating as many ratios per probe as there are reference probes. Subsequently, the median of
all these produced ratios per probe should be taken; this is the probes Normalisation Constant. This
Normalization Constant (NC), can then be used for intersample normalisation (step 2 below) and for
determining the methylation profile (7.2 PART 2: DETERMINING METHYLATION PROFILE)
2. Intersample normalisation: compare peak pattern of DNA sample of interest TO reference DNA samples.
(Reference DNA samples are derived from healthy individuals, expected to have a normal copy number and
methylation status This way, the final probe ratio for a probe is calculated, which is called the Dosage
Quotient (DQ):for the regions of interest.)
DQ probe n =
An abnormal DQ may indicate a deletion or duplication of MLPA probe targets, as shown in Figure 6. Arranging probes
according to chromosomal location facilitates the interpretation of results and may reveal more subtle changes such
as mosaicism.
Figure 6 Data analysis of the undigested reactions, providing information on copy number status. Shown is the ME028-A1
PWS/AS probemix that contains probes for the imprinted 15q11-q13 region. Left: 22 probes in the undigested test sample
(bottom) show reduced peaks (arrows) as compared to the undigested reference sample (top). Right: normalised data shows that
the 22 affected probes in the test sample (dots) form a contiguous region with a significantly lower copy number as compared to
the reference samples (boxplots), implying one copy of the region is deleted.
www.mlpa.com
page 13 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
MLPA
Dosage Quotient
0.85 < DQ < 1.15
1.35 < DQ < 1.55
1.70 < DQ < 2.20
0.35 < DQ < 0.65
0
All other values
These values are estimates. To reliably determine copy numbers, the exact cut-off values for the dosage quotients will
differ for each probe as they depend on the standard deviation of that probe. The standard deviation is affected by
DNA sample quality, selection of reference DNA samples and quality of the MLPA reaction and capillary
electrophoresis. Coffalyser.NET MLPA software is available to calculate dosage quotients taking the probe standard
deviation into account. Other software and self-made analysis sheets may be less reliable. Validate any analysis tools
prior to use by analysing known samples. Always visually inspect each MLPA reaction first, following the guidelines in
the previous chapter.
7.2.
Determine the methylation status of each MS-MLPA probe: compare the peak pattern of each digested DNA sample
TO the corresponding undigested sample. The approximate methylation percentage per probe is calculated as
follows:
[NC for MS-MLPA probe n in digested test sample A]
% methylation =
------------------------------------------------------------------ * 100%
[NC for MS-MLPA probe n in undigested test sample A]
The methylation profile of a test sample is assessed by comparing the probe methylation percentages obtained on the
test sample to the percentages of the reference samples (Figure 7). (Reference DNA samples are derived from
healthy individuals, expected to have a normal copy number and methylation status for the regions of interest.) This
way, differences in methylation status between the sample of interest and the reference samples can be identified.
Figure 7 Profile comparison of MS-MLPA data. Left: reference sample; undigested (top) and digested (bottom). Right: test
sample; undigested (top) and digested (bottom). The arrows represent the calculations that are made: horizontal arrow copy
number quantification using the undigested reaction of the reference sample and the test sample; vertical arrows methylation %
determination using the digested and undigested reaction of a sample. The methylation profile of a sample is judged by comparing
its methylation percentages to those of the reference samples (not represented by an arrow as it is not a calculation).
page 14 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
MLPA
8. INTERPRETATION OF RESULTS
To judge whether the results obtained are reliable, a good understanding of the MS-MLPA technique and the
application screened for is essential. Keep the following in mind:
MS-MLPA probe sets cannot detect deletions/duplications lying outside the target sequence of its probes. MSMLPA probes typically detect a sequence of ~55-80 nt. Most product descriptions mention only partial probe
sequences. Complete probe sequences are available on www.mlpa.com or via [email protected].
Sequence changes (SNPs, point mutations) in the probes target DNA sequence (even when not in the direct
vicinity of the ligation site) can cause false deletions. SNPs can reduce the probe signal by preventing ligation or
by destabilising the binding of the probe oligonucleotides to the sample DNA11. Confirm (especially smaller)
deletions by sequencing. Frequency of single exon deletions is generally higher in genes with large introns.
Copy number changes detected by a single probe always require confirmation by other methods. Sequencing is
often used to determine whether a mutation or polymorphism affecting the probe signal is present in the probe
target sequence. Long-range PCR and qPCR are often used to confirm (single) exon deletions. It is possible to
design your own synthetic MLPA probes for confirmation of results (e.g. Hills A. et al., (2010) Mol Cytogenet.
3:19). Information on MLPA probe design is available on www.mlpa.com.
Not all deletions and duplications detected by MLPA are pathogenic.
For many genes, exons are described that are only present in certain transcript variants. MRC-Holland cannot
provide information whether or not deletion or duplication of such exons will result in disease. For some genes,
11
When designing probes, known SNPs are avoided when possible. However, new SNPs are continuously being discovered. Please notify us when a
polymorphism or a frequent pathogenic mutation influences a probe signal.
www.mlpa.com
page 15 of 17
MRC-Holland
MS-MLPA DNA protocol version MSTP-v001; last update 09-08-2013
MLPA
in-frame deletions resulting in mild, or no disease, have been described. A duplication of one or more exons may
disrupt that copy of the gene resulting in disease, whereas a complete gene duplication may not be pathogenic.
Germline copy number variations reported in healthy individuals can be found in http://projects.tcag.ca/variation/.
Certain copy number aberrations can be due to somatic alterations. For instance, a somatic trisomy 12 is an early
sign of Chronic Lymphocytic Leukemia (CLL).
For most applications, the major cause of genetic defects will be small (point) mutations, most of which will not
be detected by SALSA MLPA kits. MLPA will not detect most inversions, translocations, nor copy number changes
that lie outside the sequence detected by the MLPA probes.
In case of poor sample DNA denaturation, even the apparent deletion of several probes recognising adjacent
genomic targets can be a false positive result! The presence of salt in DNA samples (e.g. 40 mM NaCl or 1 mM
MgCl2) prevents DNA denaturation of CG-rich chromosomal regions. Sequences in the vicinity of such CpG islands
will denature at 98o C but will reanneal immediately upon cooling as the non-denatured CpG island holds the two
strands together. Binding of certain probes to their target sequence will be hindered, resulting in reduced signals
for probes located within several kb from such strong CpG islands. This is why the D-fragments should always be
examined with great care.
MLPA tests provide the average copy number of the target sequences in the cells from which the DNA sample was
extracted. In case several probes targeting adjacent sequences have an unusual value but do not reach the usual
threshold values for a deletion/duplication, mosaicism is a possible cause.
Most MS-MLPA probes detect the methylation of the first Cytosine nucleotide in a single HhaI site within the
sequence detected by the probe (GmCGC). If methylation is absent for this particular CpG-site, it does not
necessarily mean that the whole CpG island is unmethylated! We have no data showing that methylation detected
by a particular probe indeed influences the mRNA level of that gene.
A point mutation within the HhaI site of a MS-MLPA probe may result in a false positive methylation signal as the
HhaI enzyme will not be able to digest the probe-sample DNA hybrid.
The great majority of CG sequences in the human genome located outside CpG islands is methylated. CG
sequences located within CpG islands are often protected against methylation, but the methylation status may
differ between tissues and between age groups. Sequences that are methylated in blood-derived DNA might be
unmethylated in e.g. amniotic fluid-derived DNA.
The optimal cut-off values for detecting a significant change in methylation of a sequence is probe dependent and
is dependent on sample type and application. In certain cases there might be a significant variation in methylation
of specific sequences between different normal individuals.
For many CpG islands located within imprinted chromosomal regions, one parental copy of the CpG island is
methylated while the copy inherited from the other parent is unmethylated. The average methylation quotient is
therefore 0.5. When testing samples for imprinted diseases, the threshold value for abnormal methylation can be
determined by testing sufficient DNA samples from healthy individuals.
MS-MLPA probes detecting sequences in CpG islands outside imprinting regions, e.g. in promoter regions of
genes, often reproducibly yield a low residual signal in the digested reference samples. This might be due to
methylation of the sequence in a small percentage of the cells tested. This background signal is often higher in
probes detecting sequences near the edge of the CpG island. Similarly, sequences located near the edge of a CpG
island more easily lose their protection against methylation and often show a higher frequency of methylation in
tumours.
Most MLPA probemixes contain reference probes. Copy number changes detected by reference probes are
unlikely to be related to the condition tested for. The identity of reference probes is available on request.
Analysis of parental samples might be necessary in certain cases for correct interpretation of results.
MLPA products are not CE/FDA certified. Internal MLPA technique validation in your laboratory is essential.
page 16 of 17
MRC-Holland
MLPA
www.mlpa.com
Manufacturer
Store at
Lot No.
Use by
Cat. No.
No. of Tests
page 17 of 17